Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) have received an average recommendation of "Moderate Buy" from the fourteen analysts that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $24.50.

A number of equities analysts recently issued reports on KURA shares. Mizuho dropped their price target on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, May 19th. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Friday. Cantor Fitzgerald upgraded shares of Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. JMP Securities reiterated a "market outperform" rating and issued a $28.00 price target on shares of Kura Oncology in a research note on Wednesday, June 4th. Finally, UBS Group dropped their price target on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BVF Inc. IL increased its position in shares of Kura Oncology by 202.0% during the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock valued at $51,177,000 after purchasing an additional 5,186,660 shares during the last quarter. Armistice Capital LLC increased its position in shares of Kura Oncology by 13.3% during the 1st quarter. Armistice Capital LLC now owns 6,572,000 shares of the company's stock valued at $43,375,000 after purchasing an additional 772,000 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Kura Oncology by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company's stock valued at $32,658,000 after purchasing an additional 129,337 shares during the last quarter. RA Capital Management L.P. purchased a new stake in shares of Kura Oncology during the 4th quarter valued at about $38,769,000. Finally, Millennium Management LLC increased its position in shares of Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock valued at $20,618,000 after purchasing an additional 1,521,954 shares during the last quarter.

Kura Oncology Price Performance

Shares of KURA stock opened at $5.85 on Monday. The stock has a market cap of $506.43 million, a price-to-earnings ratio of -2.79 and a beta of 0.40. The business's fifty day moving average is $6.18 and its 200 day moving average is $7.29. Kura Oncology has a twelve month low of $5.41 and a twelve month high of $23.48. The company has a quick ratio of 8.07, a current ratio of 8.07 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The firm had revenue of $14.11 million during the quarter, compared to analysts' expectations of $39.08 million. Research analysts expect that Kura Oncology will post -2.44 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.